Vita Coco CFO Corey Baker reports exercises and 10b5-1 sales
Rhea-AI Filing Summary
Corey Baker, listed as Chief Financial Officer of Vita Coco Company, Inc. (COCO), reported a series of transactions on 09/16/2025–09/18/2025. The filings show three separate acquisitions of 1,000 shares each at $16.91 and three corresponding sales of 1,000 shares each at $40. After those transactions the reporting person held 38,754 shares of common stock.
The Form 4 also discloses exercises or holdings of multiple non-qualified stock options with strike prices ranging from $16.91 to $33.36 covering in aggregate thousands of underlying shares (for example, 13,481 shares at $24.35 and 13,218 shares at $33.36). The sales of common stock were effected pursuant to a Rule 10b5-1 trading plan, as stated in the filing.
Positive
- Disclosure of 10b5-1 plan usage for the sales, indicating predefined, compliant trading arrangements
- Detailed reporting of option positions and vesting schedules, providing transparency about potential future dilution
Negative
- Insider sales of shares (three sales of 1,000 shares at $40) which represent insider liquidity rather than buy signals
- Substantial outstanding option pool across multiple strike prices that could lead to dilution if exercised
Insights
TL;DR: Insider exercised/options-related acquisitions and contemporaneous sales under a 10b5-1 plan, leaving roughly 38,754 shares held.
The pattern of identical-size acquisitions at $16.91 and sales at $40 across 09/16–09/18/2025, combined with the filing note, indicates exercises or purchases followed by programmed dispositions under a Rule 10b5-1 plan. The report lists substantial remaining option positions across multiple strike prices and vesting schedules, which represent future potential dilution if exercised. For investors, this is a routine insider liquidity event rather than a disclosure of corporate operational change.
TL;DR: Transactions appear compliant and pre-arranged; material governance concerns are not evident from the Form 4 alone.
The Form 4 explicitly states sales were effected pursuant to a Rule 10b5-1 trading plan and is signed by an attorney-in-fact, suggesting procedural compliance. The filing documents multiple option grants with varied vesting provisions, which are disclosed transparently. There is no indication in this filing of unusual timing or undisclosed related-party arrangements; however, this form does not address broader governance matters outside reported transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 1,000 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $16.91 | $17K |
| Sale | Common Stock | 1,000 | $40.00 | $40K |
| Exercise | Non-Qualified Stock Option (right to buy) | 1,000 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $16.91 | $17K |
| Sale | Common Stock | 1,000 | $40.00 | $40K |
| Exercise | Non-Qualified Stock Option (right to buy) | 1,000 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $16.91 | $17K |
| Sale | Common Stock | 1,000 | $40.00 | $40K |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan. The stock option vests in four equal annual installments beginning on March 10, 2024. The stock option is vested as to 40% and will vest the remaining 30% on March 10, 2025, 20% on March 10, 2026 and 10% on March 10, 2027. The stock option vests in four equal annual installments beginning on March 4, 2025. The Reporting Person was granted stock options that will vest in four annual equal installments on each anniversary of the grant date provided that the Reporting Person remains in continuous service on each vesting date.
